Zordani Richard A. Jr. 4

What Happened
Richard A. Zordani Jr., a director of Galectin Therapeutics, was granted 60,000 stock options (reported as a derivative award) on January 16, 2026. The Form 4 reports an acquisition price of $0.00 for the award (standard reporting for option grants); these were not exercised or sold. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and vest 100% on December 31, 2026.

Key Details

• Transaction date: January 16, 2026 (Grant/Award of options).
• Reported acquisition price: $0.00 (derivative award reporting).
• Number of options: 60,000.
• Vesting: 100% vests on December 31, 2026 (per footnote).
• Plan: Issued under the 2019 Omnibus Equity Incentive Plan.
• Filing date: January 21, 2026; filing appears to be timely (filed within required business-day window).
• Shares/options owned after transaction: Not specified in the summary data here — see the full Form 4 for total holdings.

Context
This was a compensation/award grant of stock options — not a market purchase or sale and not an exercise. The options only convert to potential equity if exercised in the future and only after vesting; their eventual value depends on the exercise price and the company’s stock performance. Awards to directors are commonly part of routine compensation and do not by themselves indicate an insider’s intent to buy or sell shares.